Atreca to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Rhea-AI Summary

Atreca, Inc. (NASDAQ: BCEL), a clinical-stage biotechnology company, announced that CEO John A. Orwin will participate in a panel discussion on T-Cells and "Informative B-Cells" at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 20, 2023, from 10:00 to 10:45 AM ET. The panel aims to address innovative approaches in oncology. A live webcast will be available for registered attendees, who can also schedule one-on-one meetings with Atreca's management. The company's unique discovery platform focuses on developing novel therapeutics based on the human immune response, leading to candidates like ATRC-101, currently in a Phase 1b study for solid tumor cancers. For more details, visit Atreca's website.

SAN CARLOS, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that John A. Orwin, President and Chief Executive Officer, will be participating in a panel discussion on T-Cells and “Informative B-Cells” at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 20^th, 2023, from 10:00 to 10:45 AM ET.

A live webcast of the panel will be available to registered conference attendees through the conference portal. Atreca management will also be participating in virtual one-on-one investor meetings during the conference. Registered attendees interested in scheduling a meeting may do so by contacting their Canaccord representative.

About Atreca, Inc.

Atreca is a biopharmaceutical company developing novel antibody-based therapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

Forward-Looking Statements

This release contains statements regarding matters that are not historical facts that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding our strategy and future plans, including statements regarding the development of ATRC-101, and our preclinical and clinical plans and the timing thereof. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

Contacts

Atreca, Inc.
Herb Cross
Chief Financial Officer
info@atreca.com

Investors:
Alex Gray, 650-779-9251
agray@atreca.com

Media:
Julia Fuller, 858-692-2001
Julia@fordhutmanmedia.com

FAQ

What is the date and time of Atreca's panel discussion at the Canaccord Genuity conference?

Atreca's panel discussion will take place on April 20, 2023, from 10:00 to 10:45 AM ET.

Who will be speaking on behalf of Atreca at the oncology conference?

John A. Orwin, President and CEO of Atreca, will be speaking at the conference.

What is the focus of Atreca's research and development?

Atreca focuses on developing novel antibody-based therapeutics through their unique discovery platform targeting oncology.

What is ATRC-101, and what stage is it currently in?

ATRC-101 is Atreca's lead product candidate, currently undergoing a Phase 1b study for multiple solid tumor cancers.

Where can I find more information about Atreca?

More information about Atreca can be found on their official website at www.atreca.com.